In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols
In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols
复制标题
DOI：
10.3109/10837450.2011.591803
复制
发表时间：
2011-11-01
影响因子：
3.4
通讯作者：
Hickey, Anthony J.
中科院分区：
文献类型：
--
作者：
Alexander, Barbara D.;Winkler, Thomas P.;Hickey, Anthony J.
药用气雾剂具有预防肺部传染病的潜力。脂体两性霉素B （LAMB, Ambisome T, Astellas Pharma US, Deerfield， IL， USA）被批准作为静脉输注药物，用于实验性治疗中性粒细胞减少症、发热患者以及感染曲霉、隐球菌和其他真菌病原体的患者。在这项研究中，通过惯性采样技术测试了四种不同雾化器在与肺沉积相关的空气动力学液滴尺寸范围内输送LAMB的能力
Pharmaceutical aerosols have the potential to prevent pulmonary infectious diseases. Liposomal amphotericin B (LAMB, Ambisome T, Astellas Pharma US, Deerfield, IL, USA) is approved as an intravenous infusion for empiric treatment of presumed fungal infections in neutropenic, febrile patients, as well as patients infected with Aspergillus, Cryptococcus, and other fungal pathogens. In this study, four different nebulizers were tested for their ability to deliver LAMB in aerodynamic droplet-size ranges relevant to lung deposition by an inertial sampling technique Mass median aerodynamic diameter (MMAD) and fine particle fraction percent